press release – price-sensitive

  • TURNOVER AS OF MARCH 31, 2026 EQUAL TO APPROXIMATELY 1.6 MILLION EUROS

    TURNOVER AS OF MARCH 31, 2026 EQUAL TO APPROXIMATELY 1.6 MILLION EUROS
  • SHAREHOLDERS’ MEETING OF ARTERRA BIOSCIENCE S.P.A.

    SHAREHOLDERS’ MEETING OF ARTERRA BIOSCIENCE S.P.A.
  • FINANCING AND GRANTING OF FUNDING FOR THE ‘RE-FOOD’ PROJECT IN THE AMOUNT OF €720,000

    FINANCING AND GRANTING OF FUNDING FOR THE ‘RE-FOOD’ PROJECT IN THE AMOUNT OF €720,000
  • PUBLICATION OF NOTICE OF CALL FOR ORDINARY SHAREHOLDERS’ MEETING

    PUBLICATION OF NOTICE OF CALL FOR ORDINARY SHAREHOLDERS’ MEETING
  • THE BOARD OF DIRECTORS HAS APPROVED THE DRAFT FINANCIAL STATEMENTS AS OF 31 DECEMBER 2025

    THE BOARD OF DIRECTORS HAS APPROVED THE DRAFT FINANCIAL STATEMENTS AS OF 31 DECEMBER 2025
  • TURNOVER AS OF 31 DECEMBER 2025 AMOUNTING TO €4.6 MILLION, AN INCREASE OF 11.42% COMPARED TO THE SAME PERIOD IN 2024

    TURNOVER AS OF 31 DECEMBER 2025 AMOUNTING TO €4.6 MILLION, AN INCREASE OF 11.42% COMPARED TO THE SAME PERIOD IN…
  • TRANSFER OF SHARES BY MARIA GABRIELLA COLUCCI TO SMART CAPITAL

    TRANSFER OF SHARES BY MARIA GABRIELLA COLUCCI TO SMART CAPITAL
  • ARTERRA BIOSCIENCE S.P.A.: TURNOVER AT SEPTEMBER 30, 2025, APPROXIMATELY 3.6 MILLION EUROS

    ARTERRA BIOSCIENCE S.P.A.: TURNOVER AT SEPTEMBER 30, 2025, APPROXIMATELY 3.6 MILLION EUROS
  • ARTERRA BIOSCIENCE ANNOUNCES THE SIGNING OF THE ADDENDUM TO THE VITALAB SHAREHOLDERS’ AGREEMENT

    ARTERRA BIOSCIENCE ANNOUNCES THE SIGNING OF THE ADDENDUM TO THE VITALAB SHAREHOLDERS' AGREEMENT
  • THE BOARD OF DIRECTORS HAS APPROVED THE HALF-YEARLY REPORT AS OF 30 JUNE 2025

    THE BOARD OF DIRECTORS HAS APPROVED THE HALF-YEARLY REPORT AS OF 30 JUNE 2025